Loading Events
This event has passed.

We know that the recent NICE decisions about the drugs ibrutinib and zanubrutinib are a cause for worry for many in the WM community. Our CEO, Jane Nicholson, who has been working with NICE and the drug companies involved during the processes joins us for a Q&A session about what the decisions mean for you, and what comes next.

Register now

This session is a repeat of the session being held at midday on Monday 9 May.

Share This Story, Choose Your Platform!